GlaxoSmithKline Heart Disease Treatment Fails Late Stage Trial
LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday its Phase III study for drug darapladib in the treatment of acute coronary syndrome failed to meet its primary endpoint of reducing major coronary events compared to a placebo when added to standard care. The company said that the ov Read More